Balchem Agrees to Acquire Market-Leading Vitamin K2 Producer Kappa Bioscience
Balchem is pleased to announce the acquisition of market-leading vitamin K2 producer, Kappa Bioscience. This exciting deal aligns well with our strategic focus and our vision of making the world a healthier place. Kappa Bioscience is dedicated to developing superior quality health solutions around vitamin K2 to improve the quality of life.
Kappa Bioscience is the only company offering a patented, 99.7% all-trans vitamin K2 as MK-7, identical to the K2 molecule found in nature and fully bioactive. Kappa’s leadership in the health & well-being market is driven by a passion for science, commercial expertise and integrity, all rooted in its Norwegian heritage.
The Kappa mantra of “doing it right,” is fully aligned with Balchem’s core values.
Vitamin K2 is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. It is important at all life stages, from pregnancy and early life to healthy aging. Kappa’s K2VITAL® branded vitamin K2 is the leading synthetic vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio.
To learn more about Kappa and its product offerings, click here:
Read the official press release here: Balchem-Kappa-Press-Release-6-14-22.pdf